UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 288 Grove Street, Suite 388 Braintree, MA 02184 (Address of principal executive of ices) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period end ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) 288 Grove Street, Suite 388 Braintree, MA 02184 (Addre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 94-3078125 (State or Other Juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction o ...

Financial Performance - The company reported a net loss of $3,513,000 for the three months ended June 30, 2022, compared to a net loss of $2,511,000 for the same period in 2021, indicating an increase in loss of approximately 40.0%[11] - For the six months ended June 30, 2022, the net loss was $6,702,000, up from $4,899,000 in the same period of 2021, reflecting an increase of approximately 36.7%[11] - The company experienced a net loss of $6,702,000 for the six months ended June 30, 2022, compared to a net loss of $4,899,000 for the same period in 2021, indicating an increase in losses of approximately 36.6%[10] - The company reported basic and diluted net loss per share of $0.94 for the six months ended June 30, 2022, compared to $0.69 for the same period in 2021, indicating a worsening loss per share of approximately 36.2%[11] - The company’s net cash flows from operating activities for the six months ended June 30, 2022, were $(6,131,000), compared to $(4,291,000) for the same period in 2021, indicating a worsening cash flow situation[15] Assets and Equity - As of June 30, 2022, total assets decreased to $10,542,000 from $16,767,000 as of December 31, 2021, representing a decline of approximately 37.0%[9] - The company's cash and cash equivalents decreased to $7,294,000 as of June 30, 2022, down from $13,493,000 as of December 31, 2021, a decline of approximately 46.0%[9] - Total stockholders' equity fell to $8,540,000 as of June 30, 2022, from $14,381,000 as of December 31, 2021, representing a decrease of approximately 40.5%[9] - The company had unrestricted cash, cash equivalents, and marketable securities of approximately $9,292,000 as of June 30, 2022[26] - As of June 30, 2022, the total cash equivalents were $4,593 million, down from $8,587 million as of December 31, 2021[36] Research and Development - Research and development expenses for the three months ended June 30, 2022, were $2,193,000, compared to $1,389,000 for the same period in 2021, marking an increase of approximately 57.8%[11] - Research and development expenses for the six months ended June 30, 2022, were $3,899,000, up from $2,508,000 in the same period of 2021, reflecting a year-over-year increase of approximately 55.2%[11] - The company expects to incur additional losses for the foreseeable future due to ongoing research and development activities[27] - The company has received approximately $1,500 in grants from the Israeli Innovation Authority for research and development since 2013[45] - The repayment of grants from the Israeli government is contingent upon successful completion of research and development programs and generating sales[48] Funding and Liabilities - The company may seek to raise additional funds through future issuances of debt and/or equity securities[27] - The company has a total lease liability balance of $573 million as of June 30, 2022[44] - The company has cash payments and expenses related to operating leases amounting to $172,000 for the six months ended June 30, 2022[44] - The total future lease payments as of June 30, 2022, are summarized as $626,000, with a total lease liability balance of $573,000[44] - The company’s total liabilities decreased to $2,002,000 as of June 30, 2022, from $2,386,000 as of December 31, 2021, a reduction of approximately 16.1%[9] Stock and Shareholder Information - The company had 7,108,133 shares of common stock issued and outstanding as of June 30, 2022, unchanged from December 31, 2021[9] - The company granted stock options to purchase 100,000 shares at an exercise price of $6.48 to its CEO during the six months ended June 30, 2022[10] - The company granted options to purchase 100,000 shares to its Chairman, President, and CEO at an exercise price of $6.48, vesting over 3 years[70] - An additional 87,500 shares were granted to employees and consultants at the same exercise price and vesting schedule[71] - The company has not sold any shares of common stock under the ATM Agreement to date[54] Legal and Strategic Agreements - The company entered into an At-the-Market Offering Agreement with an aggregate offering price of up to $10,000 million[54] - The strategic collaboration agreement with Stryker aims to integrate certain instruments with the company's LIBERTY Robotic System[56] - Development activities under the collaboration with Stryker are expected to commence during the second half of 2022[59] - The Company lost an appeal in a lawsuit related to its 2017 financing, resulting in a payment of approximately $3,700 to Sabby Healthcare for 83,333 shares[61] - The ongoing litigation with Empery Asset Master Ltd. seeks rescission of the Securities Purchase Agreement and return of the $6,750 purchase price[62] Accounting and Compliance - The company is currently evaluating the impact of recently issued accounting standards on its consolidated financial statements[42] - The Company has significant uncertainties regarding the impact of COVID-19 on its operations and clinical trials[30]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 94-3078125 (State or Other Jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) State or Other Jurisdiction of Incorporation or Organi ...